Financings Roundup
StemCells Prices $20M Offering For Adult Stem Cell Programs
A new public offering of 8 million stock units and 8 million Series B warrants could raise up to $20 million for StemCells Inc., of Newark, Calif. The company just completed enrollment in a Phase I/II trial of its HuCNS-SC neural stem cells in chronic spinal cord injury.